X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
slfn11 (25) 25
index medicus (14) 14
cancer (12) 12
humans (11) 11
oncology (11) 11
cisplatin (9) 9
dna damage (9) 9
nuclear proteins - genetics (8) 8
article (7) 7
cell biology (7) 7
cell line, tumor (7) 7
cells (7) 7
chemotherapy (7) 7
family (7) 7
gene expression (7) 7
nuclear proteins - metabolism (7) 7
deoxyribonucleic acid--dna (6) 6
epigenetics (6) 6
expression (6) 6
cell lines (5) 5
genes (5) 5
methylation (5) 5
ovarian cancer (5) 5
animals (4) 4
biomarker (4) 4
camptothecin (4) 4
colorectal cancer (4) 4
dna (4) 4
dna damage repair (4) 4
dna methylation (4) 4
genomes (4) 4
homologous recombination (4) 4
immunohistochemistry (4) 4
inhibitors (4) 4
lung cancer (4) 4
lung neoplasms - drug therapy (4) 4
resistance (4) 4
schlafen (4) 4
small cell lung carcinoma - drug therapy (4) 4
tumors (4) 4
atr (3) 3
biological response modifiers (3) 3
biomarkers (3) 3
breast cancer (3) 3
breast-cancer (3) 3
cancer-cells (3) 3
cisplatin - pharmacology (3) 3
dna repair (3) 3
dna-damaging agents (3) 3
drug resistance, neoplasm (3) 3
irinotecan (3) 3
mechanism (3) 3
mice (3) 3
mutation (3) 3
proteins (3) 3
reveals (3) 3
rna, small interfering - genetics (3) 3
schlafen-11 (3) 3
sensitivity (3) 3
transcription (3) 3
xenografts (3) 3
activation (2) 2
adn (2) 2
analysis (2) 2
anti-slfn11 antibody (2) 2
anticancer properties (2) 2
antineoplastic agents (2) 2
antineoplastic agents - pharmacology (2) 2
antitumor activity (2) 2
antitumor-activity (2) 2
ataxia telangiectasia mutated proteins - metabolism (2) 2
biotechnology (2) 2
cancer therapies (2) 2
carboplatin (2) 2
cell culture (2) 2
cell cycle (2) 2
cell cycle checkpoints (2) 2
chemoresistance (2) 2
chromatin (2) 2
cleavage complexes (2) 2
colorectal neoplasms - pathology (2) 2
cpg island methylation (2) 2
crispr (2) 2
dna helicase (2) 2
dna topoisomerase (2) 2
dna-repair (2) 2
drug (2) 2
drug resistance (2) 2
drug resistance, neoplasm - genetics (2) 2
drug-sensitivity (2) 2
drugs (2) 2
etoposide (2) 2
experimental design (2) 2
female (2) 2
gene (2) 2
gene knockdown techniques (2) 2
genomics (2) 2
histological score (2) 2
hydroxyurea (2) 2
identification (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 9/2015, Volume 21, Issue 18, pp. 4184 - 4193
Journal Article
ANALYTICAL AND QUANTITATIVE CYTOPATHOLOGY AND HISTOPATHOLOGY, ISSN 0884-6812, 10/2018, Volume 40, Issue 5, pp. 222 - 230
OBJECTIVE: To develop a protocol for immunohistochemistry (IHC) to determine the Schlafen 11 (SLFN11) expression in formalin-fixed, paraffin-embedded (FFPE)... 
DIAGNOSIS | CELLS | serous high grade ovarian cancer | ovarian cancer | histological score | CANCER | Schlafen-11 | FAMILY | CELL BIOLOGY | PATHOGENESIS | ovarian neoplasms | SLFN11 | anti-SLFN11 antibody | CISPLATIN | BLOCKS | RESISTANCE | IRINOTECAN | immunohistochemistry
Journal Article
JOURNAL OF VIROLOGY, ISSN 0022-538X, 08/2019, Volume 93, Issue 15
Schlafen 11 (Slfn11) is an interferon-stimulated gene that controls the synthesis of proteins by regulating tRNA abundance. Likely through this mechanism,... 
FITNESS | VIRUS-INFECTION | MECHANISM | PROTEIN-STRUCTURE | SYNONYMOUS CODON USAGE | SLFN11 | VIROLOGY | GENES | virus restriction factors | Schlafen 11 | TRANSFER-RNA | STRESS | flavivirus | REVEALS
Journal Article
Journal Article
by Peng, YJ and Wang, L and Wu, LL and Zhang, L and Nie, GJ and Guo, MZ
JOURNAL OF CANCER, ISSN 1837-9664, 2019, Volume 10, Issue 24, pp. 6124 - 6134
Background and Aim: Human SLFN11 gene encodes a protein with structural similarity to RNA helicases, which was reported to sensitize cancer cells to... 
DNA damage repair | SLFN11 | gastric cancer | MECHANISM | ONCOLOGY | methylation | RISK | cisplatin | epigenetics | SCHLAFEN | FAMILY
Journal Article
Molecular Cell, ISSN 1097-2765, 02/2018, Volume 69, Issue 3, pp. 371 - 384.e6
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2017, Volume 23, Issue 2, pp. 523 - 535
Purpose: PARP inhibitors (PARPi) are a novel class of small molecule therapeutics for small cell lung cancer (SCLC). Identification of predictors of response... 
BREAST-CANCER | INACTIVATION | TRIAL | HOMOLOGOUS RECOMBINATION REPAIR | DRUG-SENSITIVITY | DNA-DAMAGING AGENTS | ONCOLOGY | ABT-888 | PHASE-II | POLY(ADP-RIBOSE) POLYMERASE INHIBITOR | BMN 673 | Piperazines - administration & dosage | Dacarbazine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Phthalazines - administration & dosage | Humans | Etoposide - administration & dosage | Small Cell Lung Carcinoma - genetics | Small Cell Lung Carcinoma - drug therapy | Indoles - administration & dosage | Poly (ADP-Ribose) Polymerase-1 - antagonists & inhibitors | Cisplatin - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Drug Synergism | Xenograft Model Antitumor Assays | Small Cell Lung Carcinoma - pathology | Animals | Benzimidazoles - administration & dosage | Dacarbazine - analogs & derivatives | Cell Line, Tumor | Mice | Gene Expression Regulation, Neoplastic - drug effects | Genomics - methods | Nuclear Proteins - genetics | Poly (ADP-Ribose) Polymerase-1 - genetics | Immunohistochemistry | Therapy | Transcription | Lung cancer | Immunoblotting | Single-nucleotide polymorphism | Xenografts | CRISPR | Effectiveness | Small cell lung carcinoma | Etoposide | Poly(ADP-ribose) polymerase | Gene expression | Cisplatin | Scars | Inhibitors | Experimental design | Correlation analysis | Cell lines | Biomarkers | In vivo methods and tests | Temozolomide | Viability | Combinatorial analysis | Cancer | SLFN11 | small cell lung cancer | biomarker | PARP inhibition | patient-derived xenografts
Journal Article
CANCER CELL, ISSN 1535-6108, 02/2017, Volume 31, Issue 2, pp. 169 - 171
Chemotherapy resistance arises invariably in small cell lung cancer (SCLC). In this issue of Cancer Cell, Gardner et al. find that in some SCLC, EZH2 mediates... 
SLFN11 | ONCOLOGY | CANCER | CELL BIOLOGY | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Small Cell Lung Carcinoma - drug therapy | Carcinoma, Small Cell - drug therapy | Down-Regulation | Humans | Chemotherapy | Drug resistance | Lung cancer | Cancer
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 17, pp. 28575 - 28587
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 9/2019, Volume 177, Issue 2, pp. 335 - 343
Breast cancer (BC) is a heterogeneous disorder, with variable response to systemic chemotherapy. Likewise, BC shows highly complex immune activation patterns,... 
Biomarker | Medicine & Public Health | Basal-like phenotype | Oncology | Breast cancer | Immune signatures | Schlafen-11 | CELLS | METHYLATION | SUBTYPES | FAMILY | MOLECULAR PORTRAITS | SLFN11 | NEOADJUVANT CHEMOTHERAPY | CISPLATIN | ONCOLOGY | RESISTANCE | REVEALS | Chemotherapy | Analysis | Genes | Estrogen | Interferon | Biological response modifiers | T cells | Gene expression | Cancer
Journal Article
by An, R and Liu, JY and He, J and Wang, F and Zhang, Q and Yu, Q
AMERICAN JOURNAL OF CANCER RESEARCH, ISSN 2156-6976, 2019, Volume 9, Issue 9, pp. 1905 - 1905
We performed a drug repurposing screening of a US Food and Drug Administration (FDA)-approved drug compound library and identified Anagrelide (ANA), a known... 
cytokine | DRUG | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | SUBCELLULAR-LOCALIZATION | ANTITUMOR-ACTIVITY | IDENTIFICATION | MATURATION | Anagrelide | SCHLAFEN | SLFN12 | GLIOBLASTOMA | SLFN11 | ONCOLOGY | PDE3A | cancer | EXPRESSION
Journal Article
Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 3, pp. 3084 - 3097
Journal Article
Cancer Research, ISSN 0008-5472, 02/2017, Volume 77, Issue 3, pp. 601 - 612
Journal Article